CAMP
CAMP4 THERAPEUTICS CORPORATION
Set alert
3.96 USD +0.06 +1.54%
3.78 Day range 4.00
2.90 52-week range 7.13
- YTD
- -35.40%
- 1 year
- -1.74%
- Open
- 3.86
- Prev close
- 3.90
- Mkt cap
- 248.50M
- Vol
- 138.00K
- Avg vol
- 264.01K
- EPS
- -2.32
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.78
- High
- 4.00
- Forward P/E
- -2.52
- Beta
- 0.00
- Short ratio
- 2.72
- Inst. own
- 42.04%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jul 8, 2024
- 50-d avg
- 8.46
- 200-d avg
- 8.46
- 1y target
- 19.91
Key statistics
- Market cap
- 152.82M
- Enterprise value
- 162.90M
- Trailing P/E
- 0.00
- Forward P/E
- -2.52
- PEG ratio
- 0.00
- Price / sales
- 436.63
- Price / book
- 0.00
- EPS (TTM)
- -2.64
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 350.00K
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 12.61M
- Total debt
- 10.52M
- Return on equity
- 0.00%
- Shares outstanding
- 20.16M
- Short % of float
- 2.51%
- 50-day average
- 8.46
- 200-day average
- 8.46
Analyst view
Consensus: none
Price target (mean) 19.91 +402.7% upside
Now 3.96
- Target (low)
- 17.00
- Target (mean)
- 19.91
- Target (high)
- 22.63
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Jul 8, 2024
Expected Jul 8, 2024. Consensus EPS estimate -0.91409.
Financials — quick view
CAMP Revenue — quarterly 1.78M
CAMP Net income — quarterly -33.53M
CAMP EPS — quarterly -0.58
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jul 8, 2024 | May 1, 2024 | -0.92 | — | — | — |
| Jun 6, 2024 | Feb 1, 2024 | -3.22 | — | — | — |
| Jan 9, 2024 | Nov 1, 2023 | -2.30 | — | — | — |
| Oct 5, 2023 | Aug 1, 2023 | 0.46 | — | — | — |
| Jul 10, 2023 | May 1, 2023 | 0.92 | — | — | — |
| Apr 27, 2023 | Feb 1, 2023 | 0.23 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2024 | William Blair | init | — | Outperform |
| Nov 5, 2024 | Leerink Partners | init | — | Outperform |
| Nov 5, 2024 | JP Morgan | init | — | Overweight |
| Nov 5, 2024 | Piper Sandler | init | — | Overweight |
About CAMP4 THERAPEUTICS CORPORATION
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001 for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP to treat synaptic Ras GTPase activating protein 1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- camp4tx.com
News
- CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
- CAMP4 Therapeutics Receives CTA Approval From Regulatory Authorities And Ethics Committees Of Multiple EU Countries To Initiate Global Phase 1/2 ASCEND Clinical Trial Of CMP-002 At Trial Sites In European Union
- CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union
- Raymond James Initiates Coverage On Camp4 Therapeutics with Strong Buy Rating, Announces Price Target of $10
- CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease
- Needham Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $8
- CAMP4 to Participate in Chardan's 10th Annual Healthcare Conference
- CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Stock Rated “Moderate Buy” by Wall Street Brokerages
- Chardan Capital Maintains Buy on Camp4 Therapeutics, Lowers Price Target to $6
- CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002
Your note
Sign in to keep a note on CAMP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| 5AM PARTNERS VI, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 14, 2024 | 0 |
| AH EQUITY PARTNERS BIO I, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 14, 2024 | 0 |
| ENAVATE SCIENCES GP, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 14, 2024 | 0 |
| HOLTZMAN STEVEN H | Director | Conversion of Exercise of derivative security | Oct 14, 2024 | 108,946 |
| MANDEL-BREHM JOSH | Chief Executive Officer | Conversion of Exercise of derivative security | Oct 14, 2024 | 272,357 |
| NASHAT AMIR H. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 14, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios - Biotechnology | 1.13% | 227,300 | 1.72M | Oct 30, 2024 |
| Fidelity Growth Company Fund | 0.85% | 171,200 | 1.30M | Oct 30, 2024 |
| Fidelity Growth Company K6 Fund | 0.26% | 52,404 | 397.22K | Oct 30, 2024 |
| Fidelity Series Growth Company Fund | 0.22% | 43,500 | 329.73K | Oct 30, 2024 |